CoChat
Sign Up
Cited by 75Mangiferin and Mango ExtractsNatural Products and Biological ResearchNatural Antidiabetic Agents Studies

Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial

Open access
Na, Lixin, Zhang, Qiao, Jiang, Shuo, Du, Shanshan, Zhang, Wei, Li, Ying, Sun, Changhao, Niu, Yucun·2015·Scientific Reports
DOI 10.1038/srep10344PMC PMC4437311
Open this paper in CoChat — free accountOpen PDF

Abstract

Our previous studies have shown that mangiferin decreased serum triglycerides and free fatty acids (FFAs) by increasing FFAs oxidation in both animal and cell experiments. This study sought to evaluate the effects of mangiferin on serum lipid profiles in overweight patients with hyperlipidemia. Overweight patients with hyperlipidemia (serum triglyceride ≥ 1.70 mmol/L and total cholesterol ≥ 5.2 mmol/L) were included in this double-blind randomized controlled trial. Participants were randomly allocated to groups, either receiving mangiferin (150 mg/day) or identical placebo for 12 weeks. The lipid profile and serum levels of mangiferin, glucose, L-carnitine, β-hydroxybutyrate and acetoacetate were determined at baseline and 12 weeks. A total of 97 participants completed the trial. Compared with the placebo control, mangiferin supplementation significantly decreased the serum levels of triglycerides and FFAs and insulin resistance index. Mangiferin supplementation also significantly increased the serum levels of mangiferin, high-density lipoprotein cholesterol, L-carnitine, β-hydroxybutyrate and acetoacetate and increased lipoprotein lipase activity. However, there were no differences in the serum levels of total cholesterol, low-density lipoprotein cholesterol, serum glucose and insulin between groups. Mangiferin supplementation could improve serum lipid profiles by reducing serum triglycerides and FFAs in overweight patients with hyperlipidemia, partly due to the promotion of FFAs oxidation.

AI snapshot

Written from the paper’s full text.

TL;DR

In overweight patients with hyperlipidemia, 12 weeks of mangiferin supplementation (150 mg/day) significantly decreased serum triglycerides, free fatty acids, and HOMA-IR and increased HDL, LPL, L-carnitine, β-hydroxybutyrate, and acetoacetate compared with placebo. The authors conclude mangiferin improves serum lipid profiles partly by promoting FFA oxidation.

Key findings

  • Compared with placebo, mangiferin significantly decreased TG, FFA, and HOMA-IR by 14.4%, 8.4%, and 8.4%, respectively, and increased serum mangiferin, HDL, LPL, L-carnitine, β-hydroxybutyrate, and acetoacetate by 41.2%, 4.65%, 15.1%, 11.0%, 17.1%, and 16.5%, respectively.
  • There were no significant differences between groups in serum total cholesterol, LDL cholesterol, glucose, or insulin.
  • Total serum SFA, MUFA, PUFA, n-3 fatty acids, and n-6 fatty acids were significantly decreased in the mangiferin group; most individual fatty acids also decreased, except C14:0 and γ-C18:3, which did not change significantly.
  • Mangiferin supplementation had no significant effects on red blood cell, white blood cell, or platelet counts; hemoglobin; total protein; albumin; urea nitrogen; creatinine; AST; or ALT compared with control.

Methods

  • Double-blind, randomized, placebo-controlled 12-week trial registered as ChiCTR-TRC-13003962. Participants were recruited from five communities in Harbin, China; 104 eligible overweight patients with hyperlipidemia began the study and 97 completed it. Inclusion criteria included age 35–65 years, BMI ≥ 24.0, no cardiovascular disease/diabetes/liver/renal disease, and plasma TG ≥ 1.70 mmol/L plus TC ≥ 5.20 mmol/L.
  • Participants were stratified by serum TG and randomly assigned to mangiferin (150 mg/day) or identical placebo for 12 weeks, one tablet daily. Compliance was assessed by scheduled telephone interviews and counting remaining tablets every two weeks.
  • Blood chemistry was measured at baseline and 12 weeks. Between-group comparisons used ANCOVA adjusted for baseline values, serum mangiferin, age, gender, BMI, blood pressure, dietary intake, hyperlipidemia duration, and drug treatment; paired-samples t tests assessed within-group changes.

Limitations

  • The paper states that further studies are needed to evaluate and quantify the rate of FFA oxidation in overweight patients with hyperlipidemia treated by mangiferin.
  • Evident from the text: the trial had 97 completers, used a single relatively low dose (150 mg/day), lasted only 12 weeks, and was conducted in one region/population, limiting generalizability and dose/duration inferences.
  • Evident from the text: some participants were taking statins, and the proposed mechanism relies on indirect markers of FFA oxidation rather than direct measurement of oxidation rate.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/srep10344

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

0 of 13 cited sources checked · 0 supported · 0 flagged

  • Findingown data

    Mangiferin supplementation significantly increased serum mangiferin levels compared with placebo.

    “After 12 weeks of the intervention, there was a significant increase in serum mangiferin levels and a significant decrease in serum TG and FFA levels in the mangiferin supplementation group compared with the control group.”
    • Also stated in: § Discussion · plain
      “This randomized, double-blind, placebo-controlled trial revealed that mangiferin supplementation for 12 weeks significantly decreased the serum TG, FFA, and HOMA-IR levels and increased the serum mangiferin, HDL, and LPL levels in overweight patients with hyperlipidemia.”
    Quote in the paperNot a substantial claim
  • Findingown data

    Mangiferin supplementation significantly increased serum β-hydroxybutyrate levels compared with placebo.

    “Furthermore, mangiferin significantly increased the levels of serum high-density lipoprotein (HDL), L-carnitine, β-hydroxybutyrate, and acetoacetate levels.”
    • Also stated in: § Discussion · hedged
      “In conclusion, our results suggest that mangiferin can decrease the levels of serum TG and FFAs. It can also promote FFA oxidation by increasing serum L-carnitine, β-hydroxybutyrate, and acetoacetate levels in overweight patients with hyperlipidemia.”
    Quote in the paperSubstantial claim
  • Findingown data

    Mangiferin supplementation significantly increased serum L-carnitine levels compared with placebo.

    “Furthermore, mangiferin significantly increased the levels of serum high-density lipoprotein (HDL), L-carnitine, β-hydroxybutyrate, and acetoacetate levels.”
    • Also stated in: § Discussion · hedged
      “In conclusion, our results suggest that mangiferin can decrease the levels of serum TG and FFAs. It can also promote FFA oxidation by increasing serum L-carnitine, β-hydroxybutyrate, and acetoacetate levels in overweight patients with hyperlipidemia.”
    Quote in the paperSubstantial claim
  • Findingown data

    Mangiferin supplementation significantly increased serum high-density lipoprotein (HDL) cholesterol compared with placebo.

    “Furthermore, mangiferin significantly increased the levels of serum high-density lipoprotein (HDL), L-carnitine, β-hydroxybutyrate, and acetoacetate levels.”
    • Also stated in: § Discussion · plain
      “This randomized, double-blind, placebo-controlled trial revealed that mangiferin supplementation for 12 weeks significantly decreased the serum TG, FFA, and HOMA-IR levels and increased the serum mangiferin, HDL, and LPL levels in overweight patients with hyperlipidemia.”
    Quote in the paperSubstantial claim
  • Findingown data

    Mangiferin supplementation did not significantly change serum glucose or insulin levels compared with placebo.

    “However, there were no differences in the serum levels of total cholesterol, low-density lipoprotein cholesterol, serum glucose, and insulin between groups.”
    • Also stated in: § Serum lipids, serum glucose, and other metabolic variables · plain
      “Although there were no differences in serum glucose and insulin levels between the control and mangiferin groups, mangiferin supplementation significantly decreased the insulin resistance index (HOMA-IR) compared with that of the placebo group.”
    Quote in the paperNot a substantial claim
  • May combine two claims. 16
  • Classified as probably not a substantial claim. 17

  • May combine two claims.

    Findingown data

    Mangiferin supplementation did not significantly change serum total cholesterol or low-density lipoprotein (LDL) cholesterol compared with placebo.

    “However, there were no differences in the serum levels of total cholesterol, low-density lipoprotein cholesterol, serum glucose, and insulin between groups.”
    • Also stated in: § Serum lipids, serum glucose, and other metabolic variables · plain
      “No significant changes in serum TC and low-density lipoprotein (LDL) levels were found after the end of the mangiferin intervention (Table 3).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    Mangiferin supplementation significantly decreased total serum fatty acids and the total serum saturated, mono-unsaturated, poly-unsaturated, n-3, and n-6 fatty acid fractions compared with controls.

    “Total serum fatty acids, total serum saturated fatty acids (SFA), total serum mono-unsaturated fatty acids (MUFA), total serum poly-unsaturated fatty acids (PUFA), total serum n-3 fatty acids, and total serum n-6 fatty acids were significantly decreased in the mangiferin supplementation group compared with the controls.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    Mangiferin supplementation had no significant effects on red blood cell, white blood cell, and platelet counts or hemoglobin, total protein, albumin, urea nitrogen, creatinine, AST, and ALT levels compared with control.

    “Mangiferin supplementation had no significant effects on red blood cell, white blood cell, and platelet counts or hemoglobin, total protein, albumin, urea nitrogen, creatinine, aspartate aminotransferase (AST), and alanine transaminase (ALT) levels compared with the control group (Table 5).”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Findingown data

    Mangiferin supplementation did not change the serum contents of C14:0 and γ-C18:3.

    “Further analysis of the serum FFA profiles showed that the contents of most fatty acids were also significantly decreased in the mangiferin supplementation group; only the contents of C14:0 and γ-C18:3 were not changed by mangiferin intervention (Table 4).”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    Hyperlipidemia and elevated free fatty acids (FFAs) are risk factors for atherosclerosis and cardiovascular disease.

    “Hyperlipidemia and elevated free fatty acids (FFAs) are risk factors for these diseases13.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [13] Matkowski, A., Kus, P., Goralska, E. & Wozniak, D. Mangiferin - a bioactive xanthonoid, not only from mango and not just antioxidant. Mini Rev. Med. Chem. 13, 439–55 (2013).

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims.

    Interpretationreasoning

    Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia by reducing serum triglycerides and FFAs, partly due to promotion of FFA oxidation.

    “These results suggested that mangiferin supplementation could improve serum lipid profiles through the lowering of serum TG and FFA levels by promoting FFA oxidation.”
    • Also stated in: § Discussion · hedged
      “In conclusion, our results suggest that mangiferin can decrease the levels of serum TG and FFAs. It can also promote FFA oxidation by increasing serum L-carnitine, β-hydroxybutyrate, and acetoacetate levels in overweight patients with hyperlipidemia.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim.

    Study design and conductnone given

    Assignment into each study group remained concealed until participant enrollment was completed.

    “Assignment into each study group remained concealed until participant enrollment was completed.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim.

    Study design and conductown data

    The analysis adjusted for baseline values, serum mangiferin, age, gender, BMI, blood pressure, physical activity, hyperlipidemia duration, and drug treatment using ANCOVA.

    “Figure 2 shows the percentage differences in serum profiles between the mangiferin supplementation and placebo groups at the 12th week, adjusted for baseline values, serum mangiferin, age, gender, BMI, blood pressure, physical activity, hyperlipidemia duration, and drug treatment determined by an analysis of covariance (ANCOVA).”
    • Also stated in: § Statistical analysis · plain
      “The ANCOVA was adjusted for baseline values of serum mangiferin, age, gender, BMI, blood pressure, dietary intake, hyperlipidemia duration, and drug treatment.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Study design and conductown data

    Participants were stratified by serum TG levels and randomly assigned to placebo or mangiferin using a computer-generated blocked randomization schedule.

    “The participants were stratified by serum TG levels and randomly assigned to take either placebo or mangiferin (150 mg/d).”
    • Also stated in: § Study design · plain
      “The participants were assigned to either supplement A or B according to a computer-generated blocked randomization schedule.”
    Quote in the paperSubstantial claim

  • Classified as probably not a substantial claim. May combine two claims.

    Study design and conductown data

    The study was a 12-week, double-blind, placebo-controlled randomized trial.

    “This 12-week, double-blind, placebo-controlled study was registered at Current Controlled Trials (http://www.chictr.org, registration number: ChiCTR-TRC-13003962).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Study design and conductown data

    At baseline, there were no significant differences between the placebo and mangiferin groups in age, gender, BMI, blood pressure, or lipid-lowering statin drug use.

    “At baseline, there were no significant differences between the placebo and mangiferin supplementation groups with respect to age, gender, body mass index (BMI), and blood pressure. There was also no difference in the lipid-lowering statin drugs taken between the two groups (Table 1).”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Mangiferin has anti-inflammatory, anti-oxidant, and anti-diabetic effects.

    “It has been shown that mangiferin has many beneficial biological activities, including anti-inflammatory, anti-oxidant, and anti-diabetic effects141516.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites 141516

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    The study was registered at Current Controlled Trials (registration number: ChiCTR-TRC-13003962).

    “This 12-week, double-blind, placebo-controlled study was registered at Current Controlled Trials (http://www.chictr.org, registration number: ChiCTR-TRC-13003962).”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    Dietary intakes were measured with a validated semi-quantitative food-frequency questionnaire (FFQ).

    “At baseline and the 12th week, dietary intakes were measured with a validated semi-quantitative food-frequency questionnaire (FFQ).”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Study design and conductnone given

    The study was approved by the ethics committee of Harbin Medical University and written informed consent was obtained from all participants.

    “The study was approved by the ethics committee of Harbin Medical University and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    A safety monitor who was otherwise uninvolved with the study held the key to the blinded assignments in a sealed envelope until all results were obtained and analyzed.

    “A safety monitor who was otherwise uninvolved with the study held the key to the blinded assignments in a sealed envelope until all results were obtained and analyzed.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim.

    Premisecitation

    Lipoprotein lipase (LPL) is the key enzyme that hydrolyzes circulating TG, delivering FFAs to peripheral tissues for utilization and storage.

    “Lipoprotein lipase (LPL) is the key enzyme that hydrolyzes circulating TG, delivering FFAs to peripheral tissues for utilization and storage2728.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [2728]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims.

    Premisecitation

    Our previous studies confirmed that mangiferin lowered TG and FFAs in hyperlipidemic hamsters, rats, and HepG2 cell models, possibly by modulating key enzyme expression involved in inhibiting lipogenesis and promoting fatty acid oxidation in the liver.

    “Furthermore, our laboratory has also confirmed that mangiferin had the effects of lowering TG and FFAs in hyperlipidemic hamsters, rats, and hepG2 cell models, which may have been achieved by modulation of the key enzyme expression involved in inhibiting lipogenesis and promoting fatty acid oxidation in the liver1920.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [1920]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    L-carnitine and carnitine palmitoyltransferase (CPT) are essential for the translocation of long-chain fatty acids into mitochondria, and their quantities have been used for testing fatty acid metabolism.

    “L-carnitine and carnitine palmitoyltransferase (CPT) are essential for the translocation of long-chain fatty acids that have entered the mitochondria, and their quantities have been used for the testing of fatty acid metabolism35.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [35] Stephens, F.B. & Galloway, S.D. Carnitine and fat oxidation. Nestle Nutr. Inst. Workshop Ser. 76, 13–23 (2013). source

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    The major organ for FFA metabolism is the liver at rest and the muscle during activity.

    “The major organ for FFA metabolism is the liver at rest and the muscle during activity33.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [33] Votruba, S.B. & Jensen, M.D. Regional fat deposition as a factor in FFA metabolism. Annu. Rev. Nutr. 27, 149–63 (2007). source

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    β-Hydroxybutyrate and acetoacetate are the main alternative energy substrates to glucose and are mainly generated by oxidation of FFA transported into the blood and utilized as fuel for other cells; therefore, they should be elevated in parallel with increased FFA oxidation.

    “β-Hydroxybutyrate and acetoacetate (ketone body) are the main alternative energy substrates to glucose, and they are mainly generated by the oxidation of FFA that are transported into the blood and utilized as a fuel for other cells; therefore, they should also be elevated in parallel with the increase in FFA oxidation383940.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites 383940

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims.

    Premisecitation

    The mechanism by which mangiferin lowers serum TG involves either inhibition of TG synthesis or acceleration of TG decomposition.

    “The mechanism involved in lowering serum TG is either the inhibition of TG synthesis or acceleration of TG decomposition232425, and the catabolism of TG was mainly investigated in this study.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites 232425

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Classified as probably not a substantial claim.

    Premisecitation

    Serum TG is first hydrolyzed, liberating FFA during TG catabolism.

    “Serum TG is first hydrolyzed, which liberates FFA during TG catabolism26.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [26] Ringseis, R. & Eder, K. Regulation of genes involved in lipid metabolism by dietary oxidized fat. Mol. Nutr. Food Res. 55, 109–21 (2011). source

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    Approximately 10% of serum FFAs are derived from the hydrolysis of serum TG, and serum FFA levels should increase with the increase in TG hydrolysis.

    “Approximately 10% of serum FFAs are derived from the hydrolysis of serum TG, and serum FFA levels should increase with the increase in TG hydrolysis3132.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [3132]

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

24 of 24

  • The paper relies on this without support.

    The effect of mangiferin on blood lipids in overweight patients with hyperlipidemia remains unclear.

    “However, the effect of mangiferin on blood lipids in overweight patients with hyperlipidemia remains unclear.”

  • The paper relies on this without support.

    The lipid-lowering effects of mangiferin observed in animal and cell experiments will translate to overweight patients with hyperlipidemia.

    “Based on the lipid-lowering effects of mangiferin in animal and cell experiments, we conducted this double-blind randomized clinical trial to evaluate the effects of mangiferin on blood lipid profiles in overweight patients with hyperlipidemia.”
2 of 2

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Safety reporting is inconsistent, with limited long-term toxicity, immunomodulatory risk, and drug-drug interaction data.

    “Furthermore, safety reporting is inconsistent, with limited long-term toxicity, immunomodulatory risk and drug-drug interaction data, and with few studies that stratify patients by sex or age (184,185,190).”

    From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [185]

    The Discussion (page unavailable) says there had been no reports of long-duration mangiferin intervention in humans, supporting the concern about limited long-term safety data. It also reports no observed side effects during this 12-week trial. The paper does not assess whether safety reporting is inconsistent across studies or discuss immunomodulatory risks or drug–drug interaction data. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • Early human data on MGF are limited, heterogeneous, and not definitive for purified MGF.

    “Early human data are limited, heterogeneous (often extract-based) and not yet definitive for purified MGF.”

    From Mangiferin in human disease: Multifaceted mechanisms and applications (Review) (2026) · cites this paper as [185]

    The Discussion says no long-term human mangiferin intervention had previously been reported, supporting the description of early human evidence as limited. But the Methods describe this trial’s intervention as 98%-pure mangiferin, and the Discussion reports significant lipid-profile improvements after 12 weeks. The paper does not establish that human studies were often extract-based or characterize the evidence for purified mangiferin as not definitive. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

  • Mangiferin may improve lipid metabolism in overweight and dyslipidemic patients.

    “Their findings suggest that mangiferin may improve lipid metabolism in individuals with these conditions.”

    From Mangifera indica L., By-Products, and Mangiferin on Cardio-Metabolic and Other Health Conditions: A Systematic Review (2023) · cites this paper as [45]

  • Na et al. had a broad age range.

    “due to the broad age range included in the study”

    From Mangifera indica L., By-Products, and Mangiferin on Cardio-Metabolic and Other Health Conditions: A Systematic Review (2023) · cites this paper as [45]

  • In the same trial, mangiferin did not effectively decrease serum levels of total cholesterol, LDL-C, serum glucose or insulin.

    “However, mangiferin did not effectively decrease serum levels of total cholesterol, low-density lipoprotein cholesterol, serum glucose or insulin (87).”

    From Mangiferin: An effective therapeutic agent against several disorders (Review) (2018) · cites this paper as [87]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • ANCOVA adjustment variables differ between Results and Methods

    Minor

    The Results say the Figure 2 analysis was adjusted for physical activity, while the Statistical analysis section lists dietary intake instead. The paper gives two different adjustment sets for the reported percentage differences.

1 of 1

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Lucchi, T. & Vergani, C. [Dyslipidemias and statins: from guidelines to clinical practice. An updated review of the literature]. G Ital Cardiol (Rome). 15, 149–60 (2014).
  2. Lam, T.K. & Leung, D.T. More on simplified calculation of body-surface area. N Engl. J. Med. 318, 1130 (1988).

Cited by

Sorted by citations

Related

Authors
Na, L., Zhang, Q., Jiang, S., Du, S., Zhang, W., Li, Y., Sun, C., & Niu, Y.
Affiliations
Harbin Medical University (CN)
ORCID
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2015-05-19
Volume
5
Issue
1
Pages
10344-10344
ISSN
2045-2322 (ISSN-L)
DOI
10.1038/srep10344
PMC
PMC4437311
OpenAlex
W2255705385
Semantic Scholar
5bdac25d2afd1cba0a0f1e2522be9569eb1f7eaa
Cited by
74
References
45
Citations by year
2026: 3 · 2025: 12 · 2024: 6 · 2023: 9 · 2022: 6 · 2021: 6 · 2020: 6 · 2019: 8 · 2018: 7 · 2017: 5 · 2016: 5 · 2015: 1
FWCI
10.67
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (submittedVersion, cc-by)
Funders
  • Harbin Medical University
  • National Natural Science Foundation of China (81372997, 81130049)
  • China Postdoctoral Science Foundation
Topics
  • Health Sciences › Medicine › Complementary and alternative medicine › Mangiferin and Mango Extracts
  • Health Sciences › Medicine › Surgery › Natural Products and Biological Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
Keywords
mangiferin, hyperlipidemia, overweight, lipid profile, triglycerides, free fatty acids, fatty acid oxidation, insulin resistance, L-carnitine, beta-hydroxybutyrate, acetoacetate, lipoprotein lipase, HDL cholesterol, dietary supplementation
MeSH terms
Acetoacetates, Blood Glucose, Carnitine, Double-Blind Method, Fatty Acids, Nonesterified, Female, Humans, Hyperlipidemias, Insulin Resistance, Lipids, Lipoprotein Lipase, Cholesterol, HDL, Male, Middle Aged, Placebos, Dietary Supplements, 3-Hydroxybutyric Acid, Xanthones, Overweight

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-12.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-12.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review